Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HIV Vaccine Blueprint Calls For Industry R&D Model, Clinical Trials Network

This article was originally published in The Pink Sheet Daily

Executive Summary

Governments also must provide push-and-pull incentives for vaccine development, the International AIDS Vaccine Initiative says.

You may also be interested in...

NIH HIV Vaccine Survey Finds Misconceptions Among Highly Affected Communities

Minority recruitment into HIV vaccine trials could be a serious issue based on attitudes and knowledge revealed in a recent survey, one of the survey authors suggests.

AIDS Vaccine R&D Incentives Could Be Modeled On BioShield, Group Suggests

Creating incentives for the private sector to enter into HIV/AIDS vaccine research and development efforts is one suggestion from the International AIDS Vaccine Initiative in a new report released at the 15th International AIDS Conference in Bangkok.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts